<?xml version="1.0" encoding="UTF-8"?>
<urlset
  xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
  xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.weightlossrankings.org/research/glp1-insurance-dropped-coverage-appeal-playbook</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Insurance Dropped Your GLP-1? The Complete Appeal Playbook for CVS Caremark, Cigna, Aetna, UHC (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/qsymia-phentermine-topiramate-weight-loss-evidence</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Qsymia (Phentermine + Topiramate ER) for Weight Loss: FDA Label, CONQUER Evidence &amp; How It Compares to GLP-1s (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/best-appetite-suppressant-fda-approved-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Best Appetite Suppressant 2026: FDA-Approved Pills, Injections &amp; Drugs Compared</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/ozempic-alternatives-complete-guide-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Ozempic Alternatives (2026): FDA-Approved GLP-1s, Cheaper Semaglutide &amp; Non-GLP-1 Options</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/zepbound-generic-tirzepatide-biosimilar-timeline</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Zepbound Generic / Tirzepatide Biosimilar: When Will It Be Available? (2026 Status)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/zepbound-vs-wegovy-side-effects-comparison</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Zepbound vs Wegovy Side Effects: Head-to-Head Comparison from the FDA Labels (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/diabetes-vs-weight-loss-glp1-medication-disambiguation</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Diabetes Weight Loss Drug — Which Is Which? Untangling Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/wegovy-vs-mounjaro-different-molecules-decision-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Wegovy vs Mounjaro: Different Molecules, Different Indications — How to Choose (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/wegovy-goodrx-glp1-cash-pay-coupon-channel-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Wegovy GoodRx, NovoCare $299, Costco $349, Sam&apos;s Club: Every GLP-1 Cash-Pay Coupon &amp; Channel (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/mounjaro-vs-zepbound-complete-comparison</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Mounjaro vs Zepbound: Same Drug, Different Brand Names — Complete Side-by-Side Comparison (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/bariatric-surgery-vs-glp1-decision-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Bariatric Surgery vs GLP-1 vs Combination: A Decision Guide With 13 Verified Trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/aetna-glp1-prior-authorization-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Aetna GLP-1 Prior Authorization Guide: Verbatim PA Criteria for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/cigna-glp1-prior-authorization-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Cigna GLP-1 Prior Authorization Guide: Verbatim PA Criteria for Wegovy, Zepbound, Foundayo, Ozempic, and Mounjaro (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/aetna-glp1-autorizacion-previa-guia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Guía de autorización previa de Aetna para GLP-1: criterios textuales para Wegovy, Zepbound, Saxenda, Ozempic y Mounjaro (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/cigna-glp1-autorizacion-previa-guia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Guía de autorización previa de Cigna para GLP-1: criterios textuales para Wegovy, Zepbound, Foundayo, Ozempic y Mounjaro (2026)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/cirugia-bariatrica-vs-glp1-guia-decision</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Cirugía bariátrica vs GLP-1 vs combinación: guía de decisión con 13 ensayos verificados</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/mounjaro-zepbound-fda-prescribing-information-explained</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Mounjaro vs Zepbound: FDA Prescribing Information Explained Side-by-Side</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/mounjaro-zepbound-informacion-prescripcion-fda</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Mounjaro vs Zepbound: La información de prescripción de la FDA explicada lado a lado</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/glp1-bone-density-fracture-risk-evidence</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 Medications and Bone Density / Fracture Risk: What the Meta-Analyses, Cohort Data, and Older-Adult Sub-Analyses Actually Show</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/glp1-densidad-osea-riesgo-fractura-evidencia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 y densidad ósea / riesgo de fractura: lo que muestran los metanálisis, los datos de cohortes y los subanálisis en adultos mayores</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/ozempic-face-glp1-facial-volume-loss-evidence</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>Ozempic Face: GLP-1-Related Facial Volume Loss — What the Imaging Data and the Aesthetic-Surgery Literature Actually Show</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/ozempic-face-glp1-perdida-volumen-facial-evidencia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>&quot;Ozempic face&quot;: pérdida de volumen facial con GLP-1 — lo que muestran los datos de imágenes y la literatura quirúrgica estética</news:title>
    </news:news>
  </url>
</urlset>